| DC Field | Value | Language |
|---|
| dc.contributor.author | Antsiferov, O. V. | - |
| dc.contributor.author | Cherevatenko, R. F. | - |
| dc.contributor.author | Korokin, M. V. | - |
| dc.contributor.author | Gureev, V. V. | - |
| dc.contributor.author | Kolesnik, I. M. | - |
| dc.date.accessioned | 2022-05-11T09:19:41Z | - |
| dc.date.available | 2022-05-11T09:19:41Z | - |
| dc.date.issued | 2021 | - |
| dc.identifier.citation | A new EPOR/CD131 heteroreceptor agonist EP-11-1: a neuroprotective effect in experimental traumatic brain injury / O.V. Antsiferov [et al.] // Research Results in Pharmacology. - 2021. - Vol.7, №4.-P. 1-9. - Doi: 10.3897/rrpharmacology.7.75301. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46656 | - |
| dc.description.abstract | EP-11-1 (UEHLERALNSS) is a short-chain erythropoietin derivative without have erythropoietic activity. It was created by modifying a peptide mimicking the spatial structure of the erythropoietin a-helix B pHBSP. One of the promising directions of its administration is the correction of morphofunctional disorders that occur in traumatic brain injury (TBI) | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | traumatic brain injury | ru |
| dc.subject | secondary failure | ru |
| dc.subject | trimetazidine | ru |
| dc.subject | erythropoietin derivatives | ru |
| dc.title | A new EPOR/CD131 heteroreceptor agonist EP-11-1: a neuroprotective effect in experimental traumatic brain injury | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 7, № 4
|
